Cargando…
Treatment with docetaxel and cisplatin in advanced adrenocortical carcinoma, a phase II study
BACKGROUND: Adrenocortical carcinoma (ACC) is a rare disease with a poor response to chemotherapy. Cisplatin is the most widely investigated drug in the treatment of ACC and in vitro studies have indicated activity of taxanes. The objectives of this study were to evaluate the efficacy and toxicity o...
Autores principales: | Urup, T, Pawlak, W Z, Petersen, P M, Pappot, H, Rørth, M, Daugaard, G |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3670472/ https://www.ncbi.nlm.nih.gov/pubmed/23652308 http://dx.doi.org/10.1038/bjc.2013.229 |
Ejemplares similares
-
Phase II trial of docetaxel, cisplatin and fluorouracil followed by carboplatin and radiotherapy in locally advanced oesophageal cancer
por: Chiarion-Sileni, V, et al.
Publicado: (2007) -
Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer
por: del Muro, X García, et al.
Publicado: (2002) -
Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II study
por: Ardavanis, A, et al.
Publicado: (2005) -
Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial
por: Tebbutt, Niall C, et al.
Publicado: (2016) -
Phase I trial of docetaxel, cisplatin and concurrent radical radiotherapy in locally advanced oesophageal cancer
por: Day, F L, et al.
Publicado: (2011)